• Product nameAnti-HtrA2 / Omi antibody [196C429]
    See all HtrA2 / Omi primary antibodies
  • Description
    Mouse monoclonal [196C429] to HtrA2 / Omi
  • Tested applicationsSuitable for: IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide:


    , corresponding to amino acids 335-350 of Human HtrA2.

  • Positive control
    • Jurkat; HL-60



Our Abpromise guarantee covers the use of ab13678 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesIHC-P: 1/25. Use at an assay dependent dilution. Antigen recovery was performed by heating the sections in 10mM boiling sodium citrate buffer (pH 6.0) for 10 min. Perform antibody incubation overnight at 4oC. For further details please see Lee et al., 2003.

    WB: Use at a concentration of 2 - 3 µg/ml. Detects a band of approximately 50 & 38 kDa (predicted molecular weight: 55 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionSerine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive.
    • Tissue specificityIsoform 1 is ubiquitous. Isoform 2 is expressed predominantly in the kidney, colon and thyroid.
    • Involvement in diseaseDefects in HTRA2 are the cause of Parkinson disease type 13 (PARK13) [MIM:610297]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
    • Sequence similaritiesBelongs to the peptidase S1B family.
      Contains 1 PDZ (DHR) domain.
    • DomainThe mature N-terminus is involved in the interaction with XIAP.
      The PDZ domain mediates interaction with MXI2.
    • Post-translational
      Autoproteolytically activated.
    • Cellular localizationMitochondrion intermembrane space. Mitochondrion membrane. Predominantly present in the intermembrane space. Released into the cytosol following apoptotic stimuli, such as UV treatment, and stimulation of mitochondria with caspase-8 truncated BID/tBID.
    • Information by UniProt
    • Database links
    • Alternative names
      • High temperature requirement protein A2 antibody
      • HTRA 2 antibody
      • HtrA like serine protease antibody
      • HtrA serine peptidase 2 antibody
      • HtrA, E. coli, homolog of, 2 antibody
      • HtrA2 antibody
      • HTRA2_HUMAN antibody
      • mitochondrial antibody
      • Omi stress regulated endoprotease antibody
      • Omi stress-regulated endoprotease antibody
      • PARK 13 antibody
      • PARK13 antibody
      • Protease serine 25 antibody
      • PRSS 25 antibody
      • PRSS25 antibody
      • Serine protease 25 antibody
      • Serine protease HTRA2 antibody
      • Serine protease HTRA2 mitochondrial antibody
      • Serine protease htra2 mitochondrial precursor antibody
      • Serine protease omi antibody
      • Serine proteinase OMI antibody
      see all

    Anti-HtrA2 / Omi antibody [196C429] images

    • Predicted band size : 55 kDa

      Western blot detection of HtrA2 in HL-60 cell lysate. Two protein bands of approximate molecular weight of 50 and 38 kDa were detected using ab13678 at 3 µg/ml dilution.
    • IHC testing using ab13678 shows cytoplasmic staining in stomach tumor tissue (A) and very weak staining in normal stomach tissue (B).

    References for Anti-HtrA2 / Omi antibody [196C429] (ab13678)

    This product has been referenced in:

    See 1 Publication for this product

    Product Wall

    Thank you for your enquiry. IHC was added as an application to this antibody following its application in Lee et al., 2003. I have emailed this publication in a follow up email. According to their details; IHC-P: 1/25. Use at an assay dependent ...

    Read More